* Comments by Shearman & Sterling partner Vicki Veenker on page 2, column 2, paragraph 3, in the Nov. 20, 2000, issue of BioWorld Financial Watch referred to the Oxford Gene Technology vs. Affymetrix Inc. case, and not to any cases involving Incyte Genomics Inc.

* In the March 19, 2001, issue of BioWorld Financial Watch, Jeffrey Leiden should have been identified as Abbott Laboratories Inc.'s chief scientific officer, not the CSO of Millennium Pharmaceuticals Inc.

Editor's Note: The correction already was made in BioWorld Online.